11 Nov 2008 07:00
| For immediate release | 11 November 2008 |
MINSTER PHARMACEUTICALS PLC
("Minster" or "the Company")
Notification of Interim Results
Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, announces that its interim results for the half year ended 30 September 2008 will be announced on Friday 14 November 2008.
A meeting for analysts will be held at 10am on 14 November 2008 at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.
For further information:
| Minster Pharmaceuticals plc | Tel: +44 (0) 1799 506623 |
| Paul Sharpe, Chief Executive Officer | |
| Robert Aubrey, Chief Financial Officer | |
| Buchanan Communications | Tel: +44 (0) 20 7466 5000 |
| Mark Court / Rebecca Skye Dietrich / Catherine Breen | |
| Nomura Code Securities Limited | Tel: +44 (0) 20 7776 1200 |
| Chris Collins | |
| Richard Potts |
Notes for editors:
About Minster Pharmaceuticals plc
Minster Pharmaceuticals is a drug development company focussed on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat, under development in the preventive treatment of migraine, and sabcomeline in schizophrenia. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK.
Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers and offers the potential to prevent the onset of migraine as a preferred alternative to acute treatment. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia.
Minster's near-term focus is on the development and commercialisation of its current pipeline. Its medium term strategy is to leverage the anticipated cashflows from the current pipeline by in-licensing further compounds with the ultimate objective of creating a substantial and highly efficient drug development enterprise focussed on the central nervous system.
Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visit www.minsterpharma.com .